- Home
- PCSC vs CGEN Comparison
PCSC vs CGEN Comparison
Compare PCSC & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSC
- CGEN
- Stock Information
- Founded
- PCSC 2024
- CGEN 1993
- Country
- PCSC United States
- CGEN Israel
- Employees
- PCSC N/A
- CGEN N/A
- Industry
- PCSC
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCSC
- CGEN Health Care
- Exchange
- PCSC NYSE
- CGEN Nasdaq
- Market Cap
- PCSC 114.2M
- CGEN 117.8M
- IPO Year
- PCSC 2024
- CGEN 2000
- Fundamental
- Price
- PCSC $10.54
- CGEN $1.47
- Analyst Decision
- PCSC
- CGEN Strong Buy
- Analyst Count
- PCSC 0
- CGEN 1
- Target Price
- PCSC N/A
- CGEN $4.00
- AVG Volume (30 Days)
- PCSC 549.0
- CGEN 216.5K
- Earning Date
- PCSC 01-01-0001
- CGEN 05-19-2025
- Dividend Yield
- PCSC N/A
- CGEN N/A
- EPS Growth
- PCSC N/A
- CGEN N/A
- EPS
- PCSC N/A
- CGEN N/A
- Revenue
- PCSC N/A
- CGEN $27,589,000.00
- Revenue This Year
- PCSC N/A
- CGEN $11.81
- Revenue Next Year
- PCSC N/A
- CGEN $28.37
- P/E Ratio
- PCSC $45.93
- CGEN N/A
- Revenue Growth
- PCSC N/A
- CGEN N/A
- 52 Week Low
- PCSC $10.02
- CGEN $1.13
- 52 Week High
- PCSC $10.57
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- PCSC N/A
- CGEN 53.98
- Support Level
- PCSC N/A
- CGEN $1.38
- Resistance Level
- PCSC N/A
- CGEN $1.56
- Average True Range (ATR)
- PCSC 0.00
- CGEN 0.08
- MACD
- PCSC 0.00
- CGEN 0.02
- Stochastic Oscillator
- PCSC 0.00
- CGEN 68.97
About PCSC PERCEPTIVE CAP SOLUTIONS CORP
Perceptive Capital Solutions Corp is a blank check company.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.